Bristol Myers Squibb (BMY) Depreciation & Amortization (CF) (2009 - 2026)

Bristol Myers Squibb has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $594.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 41.3% year-over-year to $594.0 million; the TTM figure through Mar 2026 stood at $3.6 billion (down 55.53% YoY), while the FY2025 annual figure was $4.0 billion, down 58.22% from the prior year.
• Depreciation & Amortization (CF) declined to $594.0 million in Q1 2026, from $977.0 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for BMY reached as high as $2.6 billion in Q2 2024 and fell as low as $594.0 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $2.4 billion (2023), against an average of $2.0 billion.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) climbed 6.74% — and 2025, when it tumbled 61.06%.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.5 billion in 2022, then declined by 2.26% to $2.5 billion in 2023, then dropped by 23.7% to $1.9 billion in 2024, then sank by 48.03% to $977.0 million in 2025, then tumbled by 39.2% to $594.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $594.0 million, $977.0 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.